Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM, Horwitz EM, Cheng J, Ridge JA, Feigenberg SJ, Cohen RB, Nicolaou N, Sherman EJ, Babb JS, Damsker JA, Langer CJ. Kramer NM, et al. Among authors: ridge ja. Head Neck. 2005 May;27(5):406-14. doi: 10.1002/hed.20163. Head Neck. 2005. PMID: 15719391 Clinical Trial.
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, Keenan E, Nicolaou N, Friedman CD, Ridge JA. Langer CJ, et al. Among authors: ridge ja. Cancer Invest. 2006 Mar;24(2):164-73. doi: 10.1080/07357900500524421. Cancer Invest. 2006. PMID: 16537186 Clinical Trial.
Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer.
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Turaka A, et al. Among authors: ridge ja. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):65-70. doi: 10.1016/j.ijrobp.2009.10.034. Epub 2010 Apr 10. Int J Radiat Oncol Biol Phys. 2011. PMID: 20385457 Free PMC article.
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Langer CJ, et al. Among authors: ridge ja. Head Neck. 1998 Aug;20(5):385-91. doi: 10.1002/(sici)1097-0347(199808)20:5<385::aid-hed5>3.0.co;2-u. Head Neck. 1998. PMID: 9663665 Clinical Trial.
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Rusthoven KE, et al. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1020-5. doi: 10.1016/j.ijrobp.2009.09.003. Epub 2010 Mar 16. Int J Radiat Oncol Biol Phys. 2010. PMID: 20231078 Clinical Trial.
230 results